ReviewLipids in health and disease2026
Hypertriglyceridaemia and its multifaceted mechanisms driving atherosclerotic cardiovascular disease.
Review in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Freeze-DriedBiomolecules · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging evidence has shown that hypertriglyceridaemia (HTG) is a significant independent residual risk factor for atherosclerotic cardiovascular disease (ASCVD), even with optimal low density lipoprotein cholesterol (LDL-C) management. Although its direct causal role in atherogenesis remains debatable, recent mechanistic insights have unveiled novel proatherogenic pathways associated with HTG. This review critically synthesises and updates the evolving evidence linking HTG to atherosclerotic pathogenesis. Here, we describe multiple mechanisms by which HTG contributes to the initiation and progression of atherosclerotic plaques. These include promotion of subendothelial cholesterol retention, induction of vascular inflammation and endothelial dysfunction, acceleration of arterial aging, and promotion of prothrombosis. Integrating these contemporary insights, this review outlines a refined scientific framework that posits that HTG is a crucial modifiable residual risk factor for ASCVD. This paradigm enables more comprehensive risk stratification and informs the development of targeted therapies to complement conventional lipid-lowering treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.